Apitegromab Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

Biologic monoclonal antibody compound Reference needs_revision Best effort · source review pending

Also known as: SRK-015, SRK015

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Components

Fully human IgG4/lambda monoclonal antibody

Best-Effort Research Profile

Apitegromab, also known as SRK-015, is a human IgG4 monoclonal antibody directed against pro/latent myostatin (GDF8). It is classified as an antibody and has been investigated primarily in spinal muscular atrophy and other muscle-related research contexts.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Mean apparent terminal half-life of approximately 24–31 days after single intravenous doses in a phase 1 study of healthy adults.

Administration Routes (Research)

Intravenous infusion

Reported Research Effects

Binds pro/latent myostatin (GDF8)
Inhibits activation of myostatin
Investigated for effects on skeletal-muscle mass and motor function

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Investigational monoclonal antibody; not characterized here as an approved human-use product. Clinical research has included spinal muscular atrophy and other muscle-related applications. Dosing and treatment instructions are intentionally omitted.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS 2278276-46-1; FDA UNII UZ54216N0Y; USAN GH-156; INN 11471; NCI Thesaurus C174923; KEGG Drug D11797; PubChem CID 405226663

Source-Backed Observations

Apitegromab is a protein biologic rather than a small-molecule chemical compound. Public authoritative records describe its molecular formula and molecular weight as estimated values for the antibody. No common reference size was identified as an appropriate catalog fact for this biologic.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Apitegromab — FDA Global Substance Registration System
https://precision.fda.gov/ginas/app/ui/substances/cddb19d6-cb4a-436b-9048-507bd1472aa5 (accessed 2026-08-28)

Study NCT05156320: Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy
https://clinicaltrials.gov/study/NCT05156320 (accessed 2026-08-28)

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015)
https://pmc.ncbi.nlm.nih.gov/articles/PMC8189951/ (accessed 2026-08-28)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.